当前位置: X-MOL 学术Int. J. Genom. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Downregulated mRNA Expression of ZNF385B Is an Independent Predictor of Breast Cancer
International Journal of Genomics ( IF 2.9 ) Pub Date : 2021-02-03 , DOI: 10.1155/2021/4301802
Ning Yan 1 , Cong Liu 1 , Fang Tian 1 , Ling Wang 2 , Yimin Wang 3 , Zhaoying Yang 1 , Yan Jiao 4 , Miao He 5
Affiliation  

Background. ZNF385B, a zinc finger protein, has been known as a potential biomarker in some neurological and hematological studies recently. Although numerous studies have demonstrated the potential function of zinc finger proteins in tumor progression, the effects of ZNF385B in breast cancer (BC) are less studied. Methods. The Oncomine database and “ESurv” tool were used to explore the differential expression of ZNF385B in pan-cancer. Furthermore, data of patients with BC were downloaded from The Cancer Genome Atlas (TCGA). The receiver operating characteristic (ROC) curve of ZNF385B expression was established to explore the diagnostic value of ZNF385B and to obtain the cut-off value of high or low ZNF385B expression in BC. The chi-square test as well as Fisher exact test was used for identification of the relationships between clinical features and ZNF385B expression. Furthermore, the effects of ZNF385B on BC patients’ survival were evaluated by the Kaplan-Meier and Cox regression. Data from the Gene Expression Omnibus (GEO) database were employed to validate the results of TCGA. Protein expression of ZNF385B in BC patient specimens was detected by immunohistochemistry (IHC) staining. Results. ZNF385B expression was downregulated in most types of cancer including BC. Low ZNF385B expression was related with survival status, overall survival (OS), and recurrence of BC. ZNF385B had modest diagnostic value, which is indicated by the area under the ROC curve (). Patients with lower ZNF385B expression had shorter OS and RFS (relapse-free survival). It had been demonstrated that low ZNF385B expression represented independent prognostic value for OS and RFS by multivariate survival analysis. The similar results were verified by datasets from the GEO database as well. The protein expression of ZNF385B was decreased in patients’ samples compared with adjacent tissues by IHC. Conclusions. Low ZNF385B expression was an independent predictor for worse prognosis of BC patients.

中文翻译:

ZNF385B 的下调 mRNA 表达是乳腺癌的独立预测因子

背景。ZNF385B 是一种锌指蛋白,最近在一些神经学和血液学研究中被认为是一种潜在的生物标志物。尽管许多研究已经证明锌指蛋白在肿瘤进展中的潜在功能,但 ZNF385B 在乳腺癌 (BC) 中的作用研究较少。方法. Oncomine 数据库和“ESurv”工具用于探索 ZNF385B 在泛癌中的差异表达。此外,BC 患者的数据是从癌症基因组图谱 (TCGA) 下载的。建立ZNF385B表达的受试者工作特征(ROC)曲线,探讨ZNF385B的诊断价值,获得BC中ZNF385B高表达或低表达的截断值。卡方检验和Fisher精确检验用于识别临床特征与ZNF385B表达之间的关系。此外,通过 Kaplan-Meier 和 Cox 回归评估 ZNF385B 对 BC 患者生存的影响。来自基因表达综合 (GEO) 数据库的数据用于验证 TCGA 的结果。结果。ZNF385B 表达在大多数类型的癌症中下调,包括 BC。ZNF385B 低表达与 BC 的生存状态、总生存期 (OS) 和复发有关。ZNF385B 具有适度的诊断价值,由 ROC 曲线下面积表示()。ZNF385B 表达较低的患者 OS 和 RFS(无复发生存期)较短。多变量生存分析表明,低 ZNF385B 表达代表 OS 和 RFS 的独立预后价值。GEO 数据库中的数据集也验证了类似的结果。通过 IHC,与邻近组织相比,患者样本中 ZNF385B 的蛋白表达降低。结论。ZNF385B 低表达是 BC 患者预后较差的独立预测因子。
更新日期:2021-02-03
down
wechat
bug